<?xml version="1.0" encoding="UTF-8"?><rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	>
<channel>
	<title>Comments on: Glaxo&#8217;s JP: Avandia Can Make A Comeback</title>
	<atom:link href="http://www.pharmalot.com/2007/11/glaxos-jp-avandia-can-make-a-comeback/feed" rel="self" type="application/rss+xml" />
	<link>http://www.pharmalot.com/2007/11/glaxos-jp-avandia-can-make-a-comeback/</link>
	<description>News, Comment and Conversation</description>
	<pubDate>Fri, 10 Feb 2012 17:51:21 +0000</pubDate>
	<generator>http://wordpress.org/?v=2.6.2</generator>
		<item>
		<title>By: Lisa Van S</title>
		<link>http://www.pharmalot.com/2007/11/glaxos-jp-avandia-can-make-a-comeback/#comment-25831</link>
		<dc:creator>Lisa Van S</dc:creator>
		<pubDate>Wed, 14 Nov 2007 13:51:10 +0000</pubDate>
		<guid isPermaLink="false">http://www.pharmalot.com/2007/11/glaxos-jp-avandia-can-make-a-comeback/#comment-25831</guid>
		<description>JP has got it right "its all in the language"

Lets not forget that Industry and FDA negotiate on what language is placed in the label.FDA and Industry are experts when it comes to downplaying the risks.....</description>
		<content:encoded><![CDATA[<p>JP has got it right &#8220;its all in the language&#8221;</p>
<p>Lets not forget that Industry and FDA negotiate on what language is placed in the label.FDA and Industry are experts when it comes to downplaying the risks&#8230;..</p>
]]></content:encoded>
	</item>
	<item>
		<title>By: Laurie</title>
		<link>http://www.pharmalot.com/2007/11/glaxos-jp-avandia-can-make-a-comeback/#comment-25707</link>
		<dc:creator>Laurie</dc:creator>
		<pubDate>Tue, 13 Nov 2007 22:39:57 +0000</pubDate>
		<guid isPermaLink="false">http://www.pharmalot.com/2007/11/glaxos-jp-avandia-can-make-a-comeback/#comment-25707</guid>
		<description>Garnier has never shown any concern over black box warnings.</description>
		<content:encoded><![CDATA[<p>Garnier has never shown any concern over black box warnings.</p>
]]></content:encoded>
	</item>
	<item>
		<title>By: Pharma Junkie</title>
		<link>http://www.pharmalot.com/2007/11/glaxos-jp-avandia-can-make-a-comeback/#comment-25680</link>
		<dc:creator>Pharma Junkie</dc:creator>
		<pubDate>Tue, 13 Nov 2007 19:20:05 +0000</pubDate>
		<guid isPermaLink="false">http://www.pharmalot.com/2007/11/glaxos-jp-avandia-can-make-a-comeback/#comment-25680</guid>
		<description>I think Garnier is more concerned than he is letting on.  But what else can he do?  Tell the press he's scared that Avandia will be avoided like the plague?  As for his statement, â€œItâ€™s not the black box that matters or the lack of black box, thatâ€™s not important to me; itâ€™s - what is it saying?â€ -- I think he's downplaying the black box in hopes that the public will look beyond it and do a little more digging before ruling Avandia out as a treatment.</description>
		<content:encoded><![CDATA[<p>I think Garnier is more concerned than he is letting on.  But what else can he do?  Tell the press he&#8217;s scared that Avandia will be avoided like the plague?  As for his statement, â€œItâ€™s not the black box that matters or the lack of black box, thatâ€™s not important to me; itâ€™s - what is it saying?â€ &#8212; I think he&#8217;s downplaying the black box in hopes that the public will look beyond it and do a little more digging before ruling Avandia out as a treatment.</p>
]]></content:encoded>
	</item>
</channel>
</rss>

<!-- Dynamic Page Served (once) in 0.150 seconds -->

